These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results